All of these compounds exhibited anti-proliferative effects exclusively in wild-type p53-harboring breast cancer cell lines or xenografts by triggering p53 downstream genes involved in cell cycle arrest and apoptosis. The gene discussed is TP53; the disease is breast carcinoma.